SpectRx buys Sterling Medivations for $4.4 million
This article was originally published in Clinica
Executive Summary
SpectRx has bought private insulin delivery company Sterling Medivations in a share deal worth around $4.4 million. Los Altos Hills, California-based Sterling has a range of FDA-cleared products, which SpectRx plans to launch from this year. The company also has several products in development or under review by the FDA, which should lead to new product introductions at regular intervals, SpectRx believes.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.